Literature DB >> 7545748

CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis.

R Ristamäki1, H Joensuu, K O Söderström, S Jalkanen.   

Abstract

The family of CD44 glycoproteins has diverse functions in cell-cell and cell-matrix interactions. The standard form of CD44 is of importance in the dissemination of lymphoma, whereas the clinical significance of the variant exon v6-containing forms of CD44 (CD44v6) is not known. The expression of different forms of CD44 was investigated by using antibodies against the constant part of CD44 (CD44c) and CD44v6 in 56 primary and 17 recurrent non-Hodgkin's lymphomas and correlated with several clinicopathological parameters and with prognosis. Fifty-seven per cent of the primary non-Hodgkin's lymphomas expressed CD44v6 and 73 per cent expressed the constant epitope. Expression of both CD44c and CD44v6 was associated with low histological grade of malignancy. CD44c expression was associated with a low cellular proliferation rate as assessed by DNA flow cytometry. Of several factors tested, high expression of the variant from v6 was the only factor that was associated with unfavourable recurrence-free survival (P = 0.04). We conclude that CD44v6 is associated with a low histological grade, but, on the other hand, with an unfavourable outcome, which suggests that the combination of CD44v6 and histological grading may form a particularly strong prognostic parameter in non-Hodgkin's lymphoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545748     DOI: 10.1002/path.1711760308

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

1.  CD44 variant exons in leukemia and lymphoma.

Authors:  Elif Akisik; Sevil Bavbek; Nejat Dalay
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

2.  The CD44v7/8 epitope as a target to restrain proliferation of fibroblast-like synoviocytes in rheumatoid arthritis.

Authors:  A Wibulswas; D Croft; I Bacarese-Hamilton; P McIntyre; E Genot; I M Kramer
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Differential expression of CD44v6 in metastases of intestinal and diffuse types of gastric carcinoma.

Authors:  E M Castellà; A Ariza; I Pellicer; A Fernández-Vasalo; I Ojanguren
Journal:  J Clin Pathol       Date:  1998-02       Impact factor: 3.411

4.  Differential expression of CD44v6 in adenocarcinoma of the pancreas: an immunohistochemical study.

Authors:  E M Castellà; A Ariza; I Ojanguren; J L Mate; X Roca; A Fernández-Vasalo; J J Navas-Palacios
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

5.  Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases.

Authors:  A Tzankov; A-C Pehrs; A Zimpfer; S Ascani; A Lugli; S Pileri; S Dirnhofer
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

6.  Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Hee Jung Kim; Chan-il Park; Byeong Woo Park; Hy-de Lee; Woo Hee Jung
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

7.  Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas.

Authors:  Alexandar Tzankov; Philip Went; Stephan Dirnhofer
Journal:  Biomark Insights       Date:  2007-11-11

Review 8.  The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer.

Authors:  Ranjeeta Thapa; George D Wilson
Journal:  Stem Cells Int       Date:  2016-04-21       Impact factor: 5.443

9.  Silencing of the CD44 gene by CpG methylation in a human gastric carcinoma cell line.

Authors:  S Sato; H Yokozaki; W Yasui; H Nikai; E Tahara
Journal:  Jpn J Cancer Res       Date:  1999-05

10.  CD44 variant isoform expression and breast cancer prognosis.

Authors:  Y Tokue; Y Matsumura; N Katsumata; T Watanabe; D Tarin; T Kakizoe
Journal:  Jpn J Cancer Res       Date:  1998-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.